23 research outputs found
Just for Dads: a groupwork programme for fathers
Just for Dads is a groupwork programme which was initiated and developed in Cork, Ireland arising out of a collaboration between Tusla/Springboard Family Support Project, Knocknaheeny/Farranree, in Cork and the School of Applied Social Studies, University College Cork. It is aimed at engaging with fathers around developing relationships with their children and was conceived out of an awareness gained through practice, research and experience of the limitations and challenges of effectively engaging men in family services. It consists of a ten week groupwork programme which highlights how important dads are to their children's development and provides opportunities for men to explore and develop their fathering role in a supportive, non-judgemental environment. Just for Dads is designed for use with all men in fathering roles, including biological, step, foster, grandparents, and social fathers. Since its inception in 2014, the initiative has been developed, cyclically implemented, and independently evaluated
MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care.
BACKGROUND: Detection and treatment of heart failure (HF) can improve quality of life and reduce premature mortality. However, symptoms such as breathlessness are common in primary care, have a variety of causes and not all patients require cardiac imaging. In systems where healthcare resources are limited, ensuring those patients who are likely to have HF undergo appropriate and timely investigation is vital. DESIGN: A decision tree was developed to assess the cost-effectiveness of using the MICE (Male, Infarction, Crepitations, Edema) decision rule compared to other diagnostic strategies to identify HF patients presenting to primary care. METHODS: Data from REFER (REFer for EchocaRdiogram), a HF diagnostic accuracy study, was used to determine which patients received the correct diagnosis decision. The model adopted a UK National Health Service (NHS) perspective. RESULTS: The current recommended National Institute for Health and Care Excellence (NICE) guidelines for identifying patients with HF was the most cost-effective option with a cost of £4400 per quality adjusted life year (QALY) gained compared to a "do nothing" strategy. That is, patients presenting with symptoms suggestive of HF should be referred straight for echocardiography if they had a history of myocardial infarction or if their NT-proBNP level was ≥400pg/ml. The MICE rule was more expensive and less effective than the other comparators. Base-case results were robust to sensitivity analyses. CONCLUSIONS: This represents the first cost-utility analysis comparing HF diagnostic strategies for symptomatic patients. Current guidelines in England were the most cost-effective option for identifying patients for confirmatory HF diagnosis. The low number of HF with Reduced Ejection Fraction patients (12%) in the REFER patient population limited the benefits of early detection
Characterization of the Novel Broad-Spectrum Kinase Inhibitor CTx-0294885 As an Affinity Reagent for Mass Spectrometry-Based Kinome Profiling
Kinase enrichment utilizing broad-spectrum kinase inhibitors enables
the identification of large proportions of the expressed kinome by
mass spectrometry. However, the existing inhibitors are still inadequate
in covering the entire kinome. Here, we identified a novel bisanilino
pyrimidine, CTx-0294885, exhibiting inhibitory activity against a
broad range of kinases in vitro, and further developed it into a Sepharose-supported
kinase capture reagent. Use of a quantitative proteomics approach
confirmed the selectivity of CTx-0294885-bound beads for kinase enrichment.
Large-scale CTx-0294885-based affinity purification followed by LC–MS/MS
led to the identification of 235 protein kinases from MDA-MB-231 cells,
including all members of the AKT family that had not been previously
detected by other broad-spectrum kinase inhibitors. Addition of CTx-0294885
to a mixture of three kinase inhibitors commonly used for kinase-enrichment
increased the number of kinase identifications to 261, representing
the largest kinome coverage from a single cell line reported to date.
Coupling phosphopeptide enrichment with affinity purification using
the four inhibitors enabled the identification of 799 high-confidence
phosphosites on 183 kinases, ∼10% of which were localized to
the activation loop, and included previously unreported phosphosites
on BMP2K, MELK, HIPK2, and PRKDC. Therefore, CTx-0294885 represents
a powerful new reagent for analysis of kinome signaling networks that
may facilitate development of targeted therapeutic strategies. Proteomics
data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the data set identifier PXD000239
Characterization of the Novel Broad-Spectrum Kinase Inhibitor CTx-0294885 As an Affinity Reagent for Mass Spectrometry-Based Kinome Profiling
Kinase enrichment utilizing broad-spectrum kinase inhibitors enables
the identification of large proportions of the expressed kinome by
mass spectrometry. However, the existing inhibitors are still inadequate
in covering the entire kinome. Here, we identified a novel bisanilino
pyrimidine, CTx-0294885, exhibiting inhibitory activity against a
broad range of kinases in vitro, and further developed it into a Sepharose-supported
kinase capture reagent. Use of a quantitative proteomics approach
confirmed the selectivity of CTx-0294885-bound beads for kinase enrichment.
Large-scale CTx-0294885-based affinity purification followed by LC–MS/MS
led to the identification of 235 protein kinases from MDA-MB-231 cells,
including all members of the AKT family that had not been previously
detected by other broad-spectrum kinase inhibitors. Addition of CTx-0294885
to a mixture of three kinase inhibitors commonly used for kinase-enrichment
increased the number of kinase identifications to 261, representing
the largest kinome coverage from a single cell line reported to date.
Coupling phosphopeptide enrichment with affinity purification using
the four inhibitors enabled the identification of 799 high-confidence
phosphosites on 183 kinases, ∼10% of which were localized to
the activation loop, and included previously unreported phosphosites
on BMP2K, MELK, HIPK2, and PRKDC. Therefore, CTx-0294885 represents
a powerful new reagent for analysis of kinome signaling networks that
may facilitate development of targeted therapeutic strategies. Proteomics
data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the data set identifier PXD000239